PG24: PGD Impact On ART Efficiency With Introduction Of Microarray Technology For 24 Chromosome Aneuploidy Testing
Time:8:15 am - 5:00 pm
Location:Boston Convention and Exhibition Center
Anver Kuliev, M.D., Ph.D. (Chair), Reproductive Genetics Institute
Santiago Munné, Ph.D. (Co-Chair), Reprogenetics
Dagan Wells, Ph.D., FRCPath, University of Oxford
Joe Leigh Simpson, M.D., March of Dimes Foundation
Developed in Cooperation with the Preimplantation Genetic Diagnosis Special Interest Group
NEEDS ASSESSMENT AND COURSE DESCRIPTION
At least 50% of oocytes and embryos from in vitro fertilization (IVF) patients of advanced reproductive age are chromosomally abnormal, contributing significantly to infertility and pregnancy loss. Because of the present controversy on the impact of preimplantation genetic testing (PGT) for aneuploidies on the improvement of assisted reproductive technology (ART), there is a need for the development of efficient and robust methods for preselection of aneuploidy-free embryos for transfer. The available methods based on morphological criteria are not sufficient for selection of embryos with the highest developmental potential. The previous methods for aneuploidy testing were based on the fluorescence in situ hybridization (FISH) technique, which has an important limitation of not detecting abnormalities of all the chromosomes. In addition, the procedure is predominantly applied at the cleavage stage, which is compromised by the high risk of mosaicism that may contribute to false positive and false negative results.
This live course is aimed at increasing the knowledge and competence of fertility specialists and laboratory professionals, but will also be of interest to a wider audience, taking into consideration the recent controversy regarding preimplantation aneuploidy testing. Faculty will introduce microarray technology, which tests for all 24 chromosomes, and the application of this technology to different biopsy materials, including polar bodies, blastomeres and blastocysts. Participants will analyze the different platforms for 24 chromosome aneuploidy testing and review data on the clinical outcome of the application of this methodology.
At the completion of this seminar, the participant will be able to:
- Evaluate the contribution of the FISH technique to the false positive and false negative results and the impact on the clinical outcome data.
- Describe the practical application of preimplantation 24 chromosome testing to PGD for chromosomal disorders.
- Explain the importance of selection of the optimal biopsy procedure for the highest accuracy of preimplantation 24 chromosome aneuploidy testing.
- Discuss the expected efficiency of 24 chromosome aneuploidy testing, depending on the type of microarray technique used and the differences of the applied biopsy procedures.